Clin Exp Otorhinolaryngol.  2009 Dec;2(4):159-163. 10.3342/ceo.2009.2.4.159.

Surgery for Laryngopharyngeal SCC in the Era of Organ Preservation

• Lefebvre J

• KMID: 1466491
• DOI: http://doi.org/10.3342/ceo.2009.2.4.159

Abstract

Over the past decades, randomized clinical trials have assessed and validated the concept of larynx preservation. This new concept has obviously modified the treatment algorithm for laryngopharyngeal squamous cell carcinoma. However surgery for larynx and hypopharynx cancer remains indicated in many cases. Initial partial surgery is indicated for early diseases. This surgery may be performed endoscopically or openly. The results are excellent in terms of local control and function. Transoral robotic surgery is under evaluation. Initial radical surgery is indicated for advanced diseases in case of very infiltrative tumor, in case of cartilage destruction or when tolerance and/or compliance to chemotherapy-based approached is questionable. Larynx preservation is to be discussed between these two situations. In randomized trials evaluating the different larynx preservation strategies, a substantial number of larynxes could be preserved without compromising disease control or survival. The best approach in terms of quality of function preservation, overall acute and late toxicity, disease control and survival is still a matter of clinical research. It must be stressed that salvage surgery is a definite part of these larynx preservation protocols in order to maintain the ultimate disease control. This discussion underscored the need of a multidisciplinary decision making and the need of a coordinated clinical research.

Keyword

Larynx preservation; Larynx; Hypopharynx; Squamous cell carcinoma

MeSH Terms

Carcinoma, Squamous Cell
Cartilage
Compliance
Decision Making
Hypopharynx
Larynx
Organ Preservation

Reference

1. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer: the Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991; 6. 13. 324(24):1685–1690. PMID: 2034244.

2. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. EORTC Head and Neck Cancer Cooperative Group. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst. 1996; 7. 03. 88(13):890–899. PMID: 8656441.

3. Lefebvre JL, Chevalier D, Luboinski B, Traissac L, Andry G, de Raucourt D, et al. Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the phase III EORTC 24891 trial [abstract]. J Clin Oncol. 2004; 7. 15. 22(14S):5531.

4. Richard JM, Sancho-Garnier H, Pessey JJ, Luboinski B, Lefebvre JL, Dehesdin D, et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol. 1998; 5. 34(3):224–228. PMID: 9692058.

5. Pignon JP, Bourhis J, Domenge C, Designe L. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000; 3. 18. 355(9208):949–955. PMID: 10768432.

6. Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009; 4. 01. 101(7):498–506. PMID: 19318632.

7. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 11. 27. 349(22):2091–2098. PMID: 14645636.

8. Forastiere AA, Maor M, Weber RS, Pajak T, Glisson B, Trotti A, et al. Long-term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx--induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy [abstract]. J Clin Oncol. 2006; 6. 20. 24(18S):5517.

9. Lefebvre JL, Rolland F, Tesselaar M, Bardet E, Leemans CR, Geoffrois L, et al. Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst. 2009; 2. 04. 101(3):142–152. PMID: 19176454.

10. Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KJ, Winquist EW, et al. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol. 2009; 5. 20(5):921–927. PMID: 19179556.

11. Bonner JA, Harari PM, Giralt J, Baselga J, Shin D, Cohen R, et al. Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx [abstract]. J Clin Oncol. 2005; 6. 01. 23(16S):5533.

12. Lefebvre J, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): preliminary results of the randomized phase II TREMPLIN study [abstract]. J Clin Oncol. 2009; 27(15S):6010.

13. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006; 9. 02. 368(9538):843–854. PMID: 16950362.

14. Silver CE, Beitler JJ, Shaha AR, Rinaldo A, Ferlito A. Current trends in initial management of laryngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol. 2009; 9. 266(9):1333–1352. PMID: 19597837.

15. Hoffman HT, Porter K, Karnell LH, Cooper JS, Weber RS, Langer CJ, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope. 2006; 9. 116(9 Pt 2):Suppl 111. 1–13. PMID: 16946667.

16. Chen AY, Halpern M. Factors predictive of survival in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2007; 12. 133(12):1270–1276. PMID: 18086971.

17. Olsen KD. Reexamining the treatment of advanced laryngeal cancer. Head Neck. 2010; 1. 32(1):1–7. PMID: 19953627.

18. Bosetti C, Bertuccio P, Levi F, Lucchini F, Negri E, La Vecchia C. Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis. Ann Oncol. 2008; 4. 19(4):631–640. PMID: 18281267.

19. Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006; 8. 01. 24(22):3693–3704. PMID: 16832122.

20. Lefebvre JL, Ang KK. Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary. Int J Radiat Oncol Biol Phys. 2009; 4. 01. 73(5):1293–1303. PMID: 19306746.

21. Lefebvre JL, Ang KK. Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary. Head Neck. 2009; 4. 31(4):429–441. PMID: 19283793.

22. Lefebvre JL. What is the role of primary surgery in the treatment of laryngeal and hypopharyngeal cancer? Hayes Martin Lecture. Arch Otolaryngol Head Neck Surg. 2000; 3. 126(3):285–288. PMID: 10721998.

23. Iro H, Waldfahrer F, Altendorf-Hofmann A, Weidenbecher M, Sauer R, Steiner W. Transoral laser surgery of supraglottic cancer: follow-up of 141 patients. Arch Otolaryngol Head Neck Surg. 1998; 11. 124(11):1245–1250. PMID: 9821928.

24. Vilaseca-Gonzalez I, Bernal-Sprekelsen M, Blanch-Alejandro JL, Moragas-Lluis M. Complications in transoral CO2 laser surgery for carcinoma of the larynx and hypopharynx. Head Neck. 2003; 5. 25(5):382–388. PMID: 12692875.

25. Motta G, Esposito E, Motta S, Tartaro G, Testa D. CO(2) laser surgery in the treatment of glottic cancer. Head Neck. 2005; 7. 27(7):566–573. PMID: 15898101.

26. Pradier O, Christiansen H, Schmidberger H, Martin A, Jackel MC, Steiner W, et al. Adjuvant radiotherapy after transoral laser microsurgery for advanced squamous carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2005; 12. 01. 63(5):1368–1377. PMID: 16169679.

27. Hinni ML, Salassa JR, Grant DG, Pearson BW, Hayden RE, Martin A, et al. Transoral laser microsurgery for advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2007; 12. 133(12):1198–1204. PMID: 18086960.

28. Olthoff A, Ewen A, Wolff HA, Hermann RM, Vorwerk H, Hille A, et al. Organ function and quality of life after transoral laser microsurgery and adjuvant radiotherapy for locally advanced laryngeal cancer. Strahlenther Onkol. 2009; 5. 185(5):303–309. PMID: 19440669.

29. Steiner W, Ambrosch P, Hess CF, Kron M. Organ preservation by transoral laser microsurgery in piriform sinus carcinoma. Otolaryngol Head Neck Surg. 2001; 1. 124(1):58–67. PMID: 11228455.

30. Rudert HH, Hoft S. Transoral carbon-dioxide laser resection of hypopharyngeal carcinoma. Eur Arch Otorhinolaryngol. 2003; 4. 260(4):198–206. PMID: 12709803.

31. Chevalier D, Laccourreye O, Brasnu D, Laccourreye H, Piquet JJ. Cricohyoidoepiglottopexy for glottic carcinoma with fixation or impaired motion of the true vocal cord: 5-year oncologic results with 112 patients. Ann Otol Rhinol Laryngol. 1997; 5. 106(5):364–369. PMID: 9153099.

32. Dufour X, Hans S, De Mones E, Brasnu D, Menard M, Laccourreye O. Local control after supracricoid partial laryngectomy for "advanced" endolaryngeal squamous cell carcinoma classified as T3. Arch Otolaryngol Head Neck Surg. 2004; 9. 130(9):1092–1099. PMID: 15381597.

33. Lima RA, Freitas EQ, Dias FL, Barbosa MM, Kligerman J, Soares JR, et al. Supracricoid laryngectomy with cricohyoidoepiglottopexy for advanced glottic cancer. Head Neck. 2006; 6. 28(6):481–486. PMID: 16470876.

34. Soudry E, Marmor Y, Hazan A, Marx S, Sadov R, Feinmesser R. Supracricoid partial laryngectomy: an alternative to total laryngectomy for locally advanced laryngeal cancers. J Laryngol Otol. 2008; 11. 122(11):1219–1223. PMID: 18534043.

35. List MA, Stracks J, Colangelo L, Butler P, Ganzenko N, Lundy D, et al. How do head and neck cancer patients prioritize treatment outcomes before initiating treatment? J Clin Oncol. 2000; 2. 18(4):877–884. PMID: 10673531.

36. List MA, Rutherford JL, Stracks J, Pauloski BR, Logemann JA, Lundy D, et al. Prioritizing treatment outcomes: head and neck cancer patients versus nonpatients. Head Neck. 2004; 2. 26(2):163–170. PMID: 14762885.

37. Weber RS, Berkey BA, Forastiere A, Cooper J, Maor M, Goepfert H, et al. Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11. Arch Otolaryngol Head Neck Surg. 2003; 1. 129(1):44–49. PMID: 12525193.

38. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008; 7. 20. 26(21):3582–3589. PMID: 18559875.